AnaptysBio Q2 collaboration revenue doubles

AnaptysBio reported a significant increase in Q2 collaboration revenue, more than doubling year-over-year. The net loss narrowed to $38.6 million from $46.7 million. The company repurchased 9.3% of its shares, indicating confidence in its financial position. Positive Phase 2b trial results for rosnilimab in rheumatoid arthritis were announced, and enrollment for a Phase 2 trial in ulcerative colitis was completed. Analysts maintain a "buy" rating, with a median 12-month price target of $45.50, reflecting a potential upside of 47.9% from its recent closing price.

)

Overview

AnaptysBio Q2 collaboration revenue more than doubles year-over-year
Net loss narrows to $38.6 mln from $46.7 mln in prior year
Co repurchased 9.3% of shares, reflecting confidence in financial position

Result Drivers

ROSNILIMAB DATA - Positive Phase 2b trial results for rosnilimab in rheumatoid arthritis with strong safety and efficacy profile
ULCERATIVE COLITIS TRIAL - Completed enrollment for Phase 2 trial with top-line data expected in Q4 2025
PIPELINE ADVANCEMENT - Ongoing Phase 1 trials for ANB033 and ANB101, with plans for a Phase 1b cohort for ANB033 in celiac disease

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $22.26

Collabor mln

ation

Revenue

Q2 EPS -$1.34

Q2 Net -$38.63

Income mln

Q2 -$26.17

Income mln

From

Operatio

Q2 $48.43

Operatin mln

Expenses

Analyst Coverage

The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 10 “strong buy” or “buy”, 2 “hold” and no “sell” or “strong sell”
The average consensus recommendation for the biotechnology & medical research peer group is “buy”
Wall Street’s median 12-month price target for AnaptysBio Inc is $45.50, about 47.9% above its August 5 closing price of $23.69

Press Release: (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)